MXPA05009162A - Metodos para determinar un regimen quimioterapeutico basado en la perdida de heterocigosidad en la posicion de sintasa de timidilato. - Google Patents
Metodos para determinar un regimen quimioterapeutico basado en la perdida de heterocigosidad en la posicion de sintasa de timidilato.Info
- Publication number
- MXPA05009162A MXPA05009162A MXPA05009162A MXPA05009162A MXPA05009162A MX PA05009162 A MXPA05009162 A MX PA05009162A MX PA05009162 A MXPA05009162 A MX PA05009162A MX PA05009162 A MXPA05009162 A MX PA05009162A MX PA05009162 A MXPA05009162 A MX PA05009162A
- Authority
- MX
- Mexico
- Prior art keywords
- heterozygosity
- loss
- thymidylate synthase
- determining
- chemotherapeutic regimen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se dirige a un metodo para pronosticar una respuesta a un regimen quimioterapeutico basado en la perdida de heterocigosidad en la posicion de sintasa de timidilato en el tejido de cancer. Este metodo comprende determinar el genotipo del tejido normal para la sintasa de timidilato de un paciente; determinar el genotipo del tejido de tumor para la sintasa de timidilato de dicho paciente; comparar el genotipo de tejido normal con el genotipo del tejido de tumor; determinar si ha ocurrido una perdida de heterocigosidad en la posicion de sintasa de timidilato en el tejido de tumor basado en la comparacion de los genotipos; y pronosticar una respuesta al regimen quimioterapeutico basada en la perdida de heterocigosidad en la muestra de tumor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/373,752 US20040170983A1 (en) | 2003-02-27 | 2003-02-27 | Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus |
| PCT/US2004/004867 WO2004075833A2 (en) | 2003-02-27 | 2004-02-20 | Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05009162A true MXPA05009162A (es) | 2005-10-26 |
Family
ID=32907701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05009162A MXPA05009162A (es) | 2003-02-27 | 2004-02-20 | Metodos para determinar un regimen quimioterapeutico basado en la perdida de heterocigosidad en la posicion de sintasa de timidilato. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040170983A1 (es) |
| EP (1) | EP1597393B1 (es) |
| JP (1) | JP2006520197A (es) |
| KR (1) | KR101109062B1 (es) |
| CN (1) | CN1777685A (es) |
| AR (1) | AR043398A1 (es) |
| AT (1) | ATE535617T1 (es) |
| AU (1) | AU2004216231B2 (es) |
| CA (1) | CA2517384C (es) |
| ES (1) | ES2377062T3 (es) |
| IL (1) | IL170217A (es) |
| MX (1) | MXPA05009162A (es) |
| NZ (1) | NZ542500A (es) |
| TW (1) | TWI346701B (es) |
| WO (1) | WO2004075833A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2609216B1 (en) | 2010-08-24 | 2016-06-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| ES2768344T3 (es) | 2011-06-17 | 2020-06-22 | Myriad Genetics Inc | Métodos y materiales para evaluar el desequilibrio alélico |
| JP6325453B2 (ja) * | 2011-12-21 | 2018-05-16 | ミリアド・ジェネティックス・インコーポレイテッド | ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| ES2687024T3 (es) | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US11149316B2 (en) | 2013-12-09 | 2021-10-19 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| ES2800673T3 (es) | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| CN108459157B (zh) * | 2018-01-11 | 2020-11-27 | 中国药科大学 | 一种预测伊立替康化疗毒性生物标志物的组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998151A (en) * | 1995-12-01 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase |
-
2003
- 2003-02-27 US US10/373,752 patent/US20040170983A1/en not_active Abandoned
-
2004
- 2004-02-13 TW TW093103498A patent/TWI346701B/zh not_active IP Right Cessation
- 2004-02-20 WO PCT/US2004/004867 patent/WO2004075833A2/en active Application Filing
- 2004-02-20 ES ES04713289T patent/ES2377062T3/es not_active Expired - Lifetime
- 2004-02-20 EP EP04713289A patent/EP1597393B1/en not_active Expired - Lifetime
- 2004-02-20 AT AT04713289T patent/ATE535617T1/de active
- 2004-02-20 JP JP2006503700A patent/JP2006520197A/ja active Pending
- 2004-02-20 KR KR1020057015973A patent/KR101109062B1/ko not_active IP Right Cessation
- 2004-02-20 MX MXPA05009162A patent/MXPA05009162A/es active IP Right Grant
- 2004-02-20 CN CNA2004800106956A patent/CN1777685A/zh active Pending
- 2004-02-20 AU AU2004216231A patent/AU2004216231B2/en not_active Ceased
- 2004-02-20 NZ NZ542500A patent/NZ542500A/en not_active IP Right Cessation
- 2004-02-20 CA CA2517384A patent/CA2517384C/en not_active Expired - Fee Related
- 2004-02-26 AR ARP040100598A patent/AR043398A1/es active IP Right Grant
-
2005
- 2005-08-10 IL IL170217A patent/IL170217A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| NZ542500A (en) | 2008-04-30 |
| EP1597393A2 (en) | 2005-11-23 |
| CA2517384C (en) | 2013-01-22 |
| IL170217A (en) | 2010-12-30 |
| AU2004216231A1 (en) | 2004-09-10 |
| AR043398A1 (es) | 2005-07-27 |
| ATE535617T1 (de) | 2011-12-15 |
| WO2004075833A2 (en) | 2004-09-10 |
| JP2006520197A (ja) | 2006-09-07 |
| KR101109062B1 (ko) | 2012-01-31 |
| TW200510546A (en) | 2005-03-16 |
| ES2377062T3 (es) | 2012-03-22 |
| AU2004216231B2 (en) | 2009-07-23 |
| US20040170983A1 (en) | 2004-09-02 |
| WO2004075833A3 (en) | 2004-11-11 |
| KR20050105498A (ko) | 2005-11-04 |
| TWI346701B (en) | 2011-08-11 |
| CA2517384A1 (en) | 2004-09-10 |
| CN1777685A (zh) | 2006-05-24 |
| EP1597393B1 (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004046098A3 (en) | Method for predicting autoimmune diseases | |
| WO2007050465A3 (en) | Improved methods for beaming | |
| WO2000052204A3 (en) | Gene expression in bladder tumors | |
| WO2008061104A3 (en) | Methods and kits for detecting prostate cancer biomarkers | |
| EP1985715A3 (en) | ESR1 and cervical cancer | |
| AU2008304205A8 (en) | Methods and systems for genomic analysis using ancestral data | |
| WO2004111641A3 (en) | Methods for detecting cancer and monitoring cancer progression | |
| WO2006047536A3 (en) | Methods and kits for detecting mutations | |
| IL193097A0 (en) | Methods and kits for early detection of cancer or predisposition thereto | |
| WO2004060302A3 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
| EP1718768A4 (en) | METHODS AND COMPOSITIONS FOR THE DETERMINATION OF TOLERANCE PHENOTYPE IN RESPECT OF GRAFFON IN A SUBJECT | |
| WO2008140774A3 (en) | Methods for diagnosing and treating prostate and lung cancer | |
| WO2004047514A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| WO2001075175A8 (en) | Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility | |
| TW200510546A (en) | Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus | |
| WO2005087948A3 (en) | Cancer treatment and assays for determining resistance to platinum-based chemotherapeutic agent | |
| WO2007081790A3 (en) | Methods for diagnosing and treating prostate cancer | |
| HK1080945A1 (en) | Method of determining risk for prostate cancer recurrence | |
| WO2005113835A3 (en) | Kits and methods for indentification, assessment, prevention and therapy of breast cancer | |
| WO2002004683A3 (en) | Method of detecting an increased susceptibility to breast cancer | |
| AU2003278211A1 (en) | Methods for detection of genetic alterations associated with cancer | |
| WO2004048546A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| AU2003233292A1 (en) | Protein c polymorphisms | |
| GB0617119D0 (en) | Method of prognosis | |
| AU2003265998A1 (en) | Methods of cardiovascular disease assessment in an individual |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |